A strategy for organ allografts without using immunosuppressants or irradiation

DOI Web Site 被引用文献2件
  • Haruo Morita
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Kikuya Sugiura
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Muneo Inaba
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Tienan Jin
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Junji Ishikawa
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Zhexiong Lian
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Yasushi Adachi
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Shinji Sogo
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Kazuya Yamanishi
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Hideo Taki
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Masakazu Adachi
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Takato Noumi
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Yasuo Kamiyama
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Robert A. Good
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701
  • Susumu Ikehara
    First Department of Pathology and First Department of Surgery, Kansai Medical University, Moriguchi City, Osaka 570, Japan; Novartis Pharma K.K., Takarazuka City, Hyogo 665, Japan; Otsuka Pharmaceutical, Inc., Tokushima 771–01, Japan; Department of Pediatrics, All Children’s Hospital, University of South Florida, St. Petersburg, FL 33701

説明

<jats:p>A strategy to achieve regular and long lasting organ and tissue allografts without using immunosuppressants and/or irradiation has been established for mice. One hundred percent of skin allografts can be induced to survive >350 days after transplantation if spleen cells from the same donors are first injected into the portal vein of the recipients. The mechanisms underlying this long-term tolerance induction can be described as follows: (<jats:italic>i</jats:italic>) donor T cells from the spleen of the donor facilitate the acceptance of the allogeneic engraftment, (<jats:italic>ii</jats:italic>) donor-specific anergy is induced in the cytotoxic T-lymphocytes of the recipients, (<jats:italic>iii</jats:italic>) T helper type 2 cells become the dominant T cells in the recipients that are accepting the skin transplants, and (<jats:italic>iv</jats:italic>) a lasting chimerism (microchimerism) is established in these recipients. This strategy, perhaps with minor modifications, might permit one also to overcome major barriers to organ allografting in humans. If this were the case, it could represent production of long lasting immunologic tolerance without need for irradiation or cytotoxic chemo-preparative regimen and as such could greatly facilitate allotransplantation free of episodes of chronic or acute rejection or toxic and damaging preparatory regimens.</jats:p>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ